The Trump administration is negotiating drug-pricing agreements with smaller biotechnology companies in April 2026, threatening 100% tariffs on imported medicines as leverage. These talks extend a strategy previously used with larger drugmakers, where the administration extracted voluntary, confidential commitments for lower prices and increased domestic manufacturing. Smaller pharmaceutical companies, previously excluded from initial negotiations, can now pledge pricing concessions to potentially avoid tariffs or new Medicare pricing policies. The negotiations offer these companies greater certainty about federal policy impacts while allowing the administration to expand its drug pricing initiative beyond major pharmaceutical firms.
Story comments
Loading comments…